Why has the Telix Pharmaceuticals share price rocketed 53% in a month?

This biopharmaceutical company has been charging ahead lately.

| More on:
Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Telix shares have exploded more than 50% in a month 
  • In the past 52 weeks, Telix shares have rocketed more than 150% 
  • Telix is developing targeted radiation therapies and diagnostic tools for cancer 

ASX 200 healthcare share Telix Pharmaceuticals Ltd (ASX: TLX) has had a stellar month.

The Telix Pharmaceuticals share price has soared 53% from $7.01 at market close on 3 April to $10.745 at the time of writing. For perspective, the S&P/ASX 200 Health Care Index (ASX: XHJ) has climbed 3% in a month.

Let's take a look at what's been weighing on Telix Pharmaceuticals shares lately.

What's going on?

Telix is developing therapeutic and diagnostic products for cancer and rare diseases using targeted radiation.

Investors appear to have bought up Telix shares in the last month on the back of multiple positive announcements.

On 1 May, Telix shares lifted on positive results from the company's phase three ZIRCON kidney cancer imaging study of TLX250-CDx in clear cell renal cell carcinoma.

New data confirmed the efficacy of TLX250-CDx in masses of 2cm or smaller. Telix chief medical officer Dr Colin Hayward said:

The excellent sensitivity and specificity for small lesions considerably expands the clinical utility and potentially the commercial opportunity for TLX250-CDx.

On 27 April, Telix announced news of a "powerful" artificial intelligence (AI) acquisition. The company unveiled plans to acquire AI-powered clinical decision support software platform Dedicaid.

Commenting on the news, Telix chief scientist Dr Michael Wheatcroft said:

This acquisition provides Telix with a powerful AI development platform that greatly enhances our ability to rapidly generate new applications from clinical imaging data.

Meanwhile, on 17 April, Telix advised it had demonstrated proof of concept using radio labelled Olaratumab to deliver diagnostic and therapeutic radiation to tumours.

Olaratumab is an antibody licensed by Eli Lilly and Company (Lilly). Telix will now progress to human clinical trials.

Also on this day, the company presented a quarter-one FY23 business update. Total revenue rose 27% on the previous quarter to $100.1 million. Compared to the $3.7 million result in the first quarter of 2022, revenue has risen 2605%.

Telix reported a net operating cash inflow of $2.4 million, up $0.8 million on the prior quarter.

Telix Pharmaceuticals share price snapshot

Telix shares have exploded 153% in the last year and nearly 48% year to date.

This ASX 200 healthcare share has a market cap of about $3.41 billion based on the latest share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

Read more »